AG˹ٷ

STOCK TITAN

[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

John Wiley & Sons, Inc. (WLYB) has filed a Form 144 indicating an intended sale of 5,665 shares of its common stock through UBS Financial Services on the NYSE, with an aggregate market value of $250,053. Based on the figures supplied, the reference price is roughly $44 per share. The shares to be sold represent approximately 0.013 % of the company’s 44.62 million shares outstanding, making the planned disposition immaterial in percentage terms.

The stock was acquired via the vesting of multiple tranches of restricted stock units (RSUs) and performance share units (RPSUs) granted between April 2021 and April 2023. Tranche sizes range from 191 to 1,565 shares, reflecting normal equity-compensation practices. The filer reported no sales during the prior three-month period and certified the absence of undisclosed material adverse information.

Form 144 is a notice of proposed, not completed, sales. The filing does not disclose the seller’s identity, whether a Rule 10b5-1 trading plan exists, or final execution prices. Given the modest size of the transaction and its origin from routine incentive-compensation vesting, the event is unlikely to influence WLYB’s share price materially, but it remains a data point for investors monitoring insider-selling patterns.

John Wiley & Sons, Inc. (WLYB) ha presentato un modulo Form 144 indicando l'intenzione di vendere 5.665 azioni ordinarie tramite UBS Financial Services alla NYSE, con un valore di mercato complessivo di 250.053 $. In base ai dati forniti, il prezzo di riferimento è di circa 44 $ per azione. Le azioni da vendere rappresentano circa lo 0,013% delle 44,62 milioni di azioni in circolazione della società, rendendo la cessione pianificata irrilevante in termini percentuali.

Le azioni sono state acquisite attraverso la maturazione di più tranche di unità azionarie vincolate (RSU) e unità azionarie basate sulle prestazioni (RPSU) concesse tra aprile 2021 e aprile 2023. Le dimensioni delle tranche variano da 191 a 1.565 azioni, riflettendo le normali pratiche di compensazione azionaria. Il dichiarante ha segnalato nessuna vendita nel trimestre precedente e ha certificato l'assenza di informazioni materiali negative non divulgate.

Il modulo Form 144 è un avviso di vendita proposta, non completata. La comunicazione non rivela l'identità del venditore, la presenza di un piano di trading secondo la Regola 10b5-1, né i prezzi finali di esecuzione. Considerata la modesta entità della transazione e la sua origine da una normale maturazione di incentivi, l'evento è poco probabile che influenzi materialmente il prezzo delle azioni di WLYB, ma rimane un dato utile per gli investitori che monitorano i modelli di vendita degli insider.

John Wiley & Sons, Inc. (WLYB) ha presentado un Formulario 144 indicando la intención de vender 5,665 acciones ordinarias a través de UBS Financial Services en la NYSE, con un valor de mercado agregado de $250,053. Según las cifras proporcionadas, el precio de referencia es aproximadamente $44 por acción. Las acciones a vender representan aproximadamente el 0,013% de las 44,62 millones de acciones en circulación de la empresa, haciendo que la disposición planeada sea insignificante en términos porcentuales.

Las acciones fueron adquiridas mediante la adquisición de múltiples tramos de unidades de acciones restringidas (RSU) y unidades de acciones basadas en desempeño (RPSU) otorgadas entre abril de 2021 y abril de 2023. Los tamaños de los tramos varían de 191 a 1,565 acciones, reflejando prácticas normales de compensación con acciones. El declarante reportó ninguna venta durante el período de tres meses anterior y certificó la ausencia de información material adversa no divulgada.

El Formulario 144 es un aviso de ventas propuestas, no completadas. La presentación no revela la identidad del vendedor, si existe un plan de negociación bajo la Regla 10b5-1, ni los precios finales de ejecución. Dada la modesta magnitud de la transacción y su origen en la adquisición rutinaria de incentivos, el evento es poco probable que influya materialmente en el precio de las acciones de WLYB, pero sigue siendo un dato para los inversores que monitorean los patrones de venta de insiders.

John Wiley & Sons, Inc. (WLYB)� NYSE에서 UBS Financial Services� 통해 보통� 5,665�� 매도� 예정임을 알리� Form 144� 제출했으�, � 시장 가치는 250,053달러입니�. 제공� 수치� 따르� 기준 주가� � 주당 44달러입니�. 매도 예정 주식은 회사� 4,462� � � � 0.013%� 해당� 비율� 중요하지 않은 규모입니�.

� 주식들은 2021� 4�붶� 2023� 4� 사이� 부여된 제한 주식 단위(RSU)와 성과 주식 단위(RPSU)� 여러 트랜치가 성숙되면� 취득� 것입니다. 트랜� 크기� 191주에� 1,565� 사이�, 일반적인 주식 보상 관행을 반영합니�. 제출자는 지� 3개월 동안 매도 내역� 없었으며 공개되지 않은 중대� 부정적 정보가 없음� 인증했습니다.

Form 144� 제안� 매도� 대� 통지� � 완료� 거래가 아닙니다. 제출서에� 매도자의 신원, Rule 10b5-1 거래 계획 존재 여부, 최종 실행 가격이 공개되어 있지 않습니다. 거래 규모가 작고 일반적인 인센티브 보상 성숙에서 비롯� 점을 감안� �, � 사건� WLYB 주가� 중대� 영향� 미칠 가능성은 낮으� 내부� 매도 패턴� 모니터링하는 투자자에게는 참고 자료가 됩니�.

John Wiley & Sons, Inc. (WLYB) a déposé un formulaire 144 indiquant la vente prévue de 5 665 actions ordinaires via UBS Financial Services à la NYSE, pour une valeur marchande totale de 250 053 $. D'après les chiffres fournis, le prix de référence est d'environ 44 $ par action. Les actions à vendre représentent environ 0,013 % des 44,62 millions d'actions en circulation de la société, ce qui rend cette cession insignifiante en pourcentage.

Les actions ont été acquises par la levée de plusieurs tranches d'unités d'actions restreintes (RSU) et d'unités d'actions de performance (RPSU) attribuées entre avril 2021 et avril 2023. Les tailles des tranches varient de 191 à 1 565 actions, reflétant les pratiques habituelles de rémunération en actions. Le déclarant a indiqué aucune vente au cours des trois mois précédents et a certifié l'absence d'informations défavorables importantes non divulguées.

Le formulaire 144 est un avis de ventes proposées, non finalisées. Le dépôt ne révèle pas l'identité du vendeur, l'existence éventuelle d'un plan de trading conforme à la règle 10b5-1, ni les prix d'exécution finaux. Compte tenu de la taille modeste de la transaction et de son origine dans une levée d'incitations courante, cet événement est peu susceptible d'influencer de manière significative le cours de l'action WLYB, mais reste un point de données pour les investisseurs surveillant les tendances de vente des initiés.

John Wiley & Sons, Inc. (WLYB) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 5.665 Stammaktien über UBS Financial Services an der NYSE mit einem Gesamtmarktwert von 250.053 $ ankündigt. Basierend auf den angegebenen Zahlen liegt der Referenzpreis bei etwa 44 $ pro Aktie. Die zum Verkauf stehenden Aktien entsprechen etwa 0,013 % der 44,62 Millionen ausstehenden Aktien des Unternehmens, wodurch die geplante Transaktion prozentual unerheblich ist.

Die Aktien wurden durch die Vesting-Phasen mehrerer Tranchen von Restricted Stock Units (RSUs) und Performance Share Units (RPSUs) erworben, die zwischen April 2021 und April 2023 gewährt wurden. Die Tranchengrößen reichen von 191 bis 1.565 Aktien und spiegeln übliche Praktiken bei Aktienvergütungen wider. Der Meldende gab an, im vorangegangenen Dreimonatszeitraum keine Verkäufe getätigt zu haben und bestätigte das Fehlen nicht offengelegter wesentlicher negativer Informationen.

Formular 144 ist eine Mitteilung über geplante, nicht abgeschlossene Verkäufe. Die Einreichung offenbart nicht die Identität des Verkäufers, ob ein Rule 10b5-1 Handelsplan besteht, noch die endgültigen Ausführungspreise. Angesichts der überschaubaren Transaktionsgröße und ihres Ursprungs aus routinemäßiger Anreizvergütung ist es unwahrscheinlich, dass dieses Ereignis den Aktienkurs von WLYB wesentlich beeinflusst, stellt jedoch einen Datenpunkt für Investoren dar, die Insider-Verkaufsmuster beobachten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider Form 144 (5,665 shares) from RSU/RPSU vesting; negligible at 0.013 % float—market impact expected to be minimal.

The filing signals intent rather than execution, so liquidity effects may never materialize. Even if fully executed, $250k in value is minor versus Wiley’s daily trading volume and market cap. The sales stem from normal equity-compensation vesting cycles and are spread across grants from 2021-2023, suggesting no abrupt change in insider sentiment. I view the disclosure as informational only and rate the impact neutral.

TL;DR: Routine equity-compensation liquidation; no red flags on governance or undisclosed information, hence neutral for investors.

Form 144 requires certification that the seller is unaware of non-public adverse information—this strengthens governance transparency. Absence of clustered insider selling or large percentage ownership changes indicates standard personal liquidity management. Because details on any Rule 10b5-1 plan are absent, investors may wish to verify future Form 4 filings for actual transactions, but nothing in this notice suggests heightened governance risk.

John Wiley & Sons, Inc. (WLYB) ha presentato un modulo Form 144 indicando l'intenzione di vendere 5.665 azioni ordinarie tramite UBS Financial Services alla NYSE, con un valore di mercato complessivo di 250.053 $. In base ai dati forniti, il prezzo di riferimento è di circa 44 $ per azione. Le azioni da vendere rappresentano circa lo 0,013% delle 44,62 milioni di azioni in circolazione della società, rendendo la cessione pianificata irrilevante in termini percentuali.

Le azioni sono state acquisite attraverso la maturazione di più tranche di unità azionarie vincolate (RSU) e unità azionarie basate sulle prestazioni (RPSU) concesse tra aprile 2021 e aprile 2023. Le dimensioni delle tranche variano da 191 a 1.565 azioni, riflettendo le normali pratiche di compensazione azionaria. Il dichiarante ha segnalato nessuna vendita nel trimestre precedente e ha certificato l'assenza di informazioni materiali negative non divulgate.

Il modulo Form 144 è un avviso di vendita proposta, non completata. La comunicazione non rivela l'identità del venditore, la presenza di un piano di trading secondo la Regola 10b5-1, né i prezzi finali di esecuzione. Considerata la modesta entità della transazione e la sua origine da una normale maturazione di incentivi, l'evento è poco probabile che influenzi materialmente il prezzo delle azioni di WLYB, ma rimane un dato utile per gli investitori che monitorano i modelli di vendita degli insider.

John Wiley & Sons, Inc. (WLYB) ha presentado un Formulario 144 indicando la intención de vender 5,665 acciones ordinarias a través de UBS Financial Services en la NYSE, con un valor de mercado agregado de $250,053. Según las cifras proporcionadas, el precio de referencia es aproximadamente $44 por acción. Las acciones a vender representan aproximadamente el 0,013% de las 44,62 millones de acciones en circulación de la empresa, haciendo que la disposición planeada sea insignificante en términos porcentuales.

Las acciones fueron adquiridas mediante la adquisición de múltiples tramos de unidades de acciones restringidas (RSU) y unidades de acciones basadas en desempeño (RPSU) otorgadas entre abril de 2021 y abril de 2023. Los tamaños de los tramos varían de 191 a 1,565 acciones, reflejando prácticas normales de compensación con acciones. El declarante reportó ninguna venta durante el período de tres meses anterior y certificó la ausencia de información material adversa no divulgada.

El Formulario 144 es un aviso de ventas propuestas, no completadas. La presentación no revela la identidad del vendedor, si existe un plan de negociación bajo la Regla 10b5-1, ni los precios finales de ejecución. Dada la modesta magnitud de la transacción y su origen en la adquisición rutinaria de incentivos, el evento es poco probable que influya materialmente en el precio de las acciones de WLYB, pero sigue siendo un dato para los inversores que monitorean los patrones de venta de insiders.

John Wiley & Sons, Inc. (WLYB)� NYSE에서 UBS Financial Services� 통해 보통� 5,665�� 매도� 예정임을 알리� Form 144� 제출했으�, � 시장 가치는 250,053달러입니�. 제공� 수치� 따르� 기준 주가� � 주당 44달러입니�. 매도 예정 주식은 회사� 4,462� � � � 0.013%� 해당� 비율� 중요하지 않은 규모입니�.

� 주식들은 2021� 4�붶� 2023� 4� 사이� 부여된 제한 주식 단위(RSU)와 성과 주식 단위(RPSU)� 여러 트랜치가 성숙되면� 취득� 것입니다. 트랜� 크기� 191주에� 1,565� 사이�, 일반적인 주식 보상 관행을 반영합니�. 제출자는 지� 3개월 동안 매도 내역� 없었으며 공개되지 않은 중대� 부정적 정보가 없음� 인증했습니다.

Form 144� 제안� 매도� 대� 통지� � 완료� 거래가 아닙니다. 제출서에� 매도자의 신원, Rule 10b5-1 거래 계획 존재 여부, 최종 실행 가격이 공개되어 있지 않습니다. 거래 규모가 작고 일반적인 인센티브 보상 성숙에서 비롯� 점을 감안� �, � 사건� WLYB 주가� 중대� 영향� 미칠 가능성은 낮으� 내부� 매도 패턴� 모니터링하는 투자자에게는 참고 자료가 됩니�.

John Wiley & Sons, Inc. (WLYB) a déposé un formulaire 144 indiquant la vente prévue de 5 665 actions ordinaires via UBS Financial Services à la NYSE, pour une valeur marchande totale de 250 053 $. D'après les chiffres fournis, le prix de référence est d'environ 44 $ par action. Les actions à vendre représentent environ 0,013 % des 44,62 millions d'actions en circulation de la société, ce qui rend cette cession insignifiante en pourcentage.

Les actions ont été acquises par la levée de plusieurs tranches d'unités d'actions restreintes (RSU) et d'unités d'actions de performance (RPSU) attribuées entre avril 2021 et avril 2023. Les tailles des tranches varient de 191 à 1 565 actions, reflétant les pratiques habituelles de rémunération en actions. Le déclarant a indiqué aucune vente au cours des trois mois précédents et a certifié l'absence d'informations défavorables importantes non divulguées.

Le formulaire 144 est un avis de ventes proposées, non finalisées. Le dépôt ne révèle pas l'identité du vendeur, l'existence éventuelle d'un plan de trading conforme à la règle 10b5-1, ni les prix d'exécution finaux. Compte tenu de la taille modeste de la transaction et de son origine dans une levée d'incitations courante, cet événement est peu susceptible d'influencer de manière significative le cours de l'action WLYB, mais reste un point de données pour les investisseurs surveillant les tendances de vente des initiés.

John Wiley & Sons, Inc. (WLYB) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 5.665 Stammaktien über UBS Financial Services an der NYSE mit einem Gesamtmarktwert von 250.053 $ ankündigt. Basierend auf den angegebenen Zahlen liegt der Referenzpreis bei etwa 44 $ pro Aktie. Die zum Verkauf stehenden Aktien entsprechen etwa 0,013 % der 44,62 Millionen ausstehenden Aktien des Unternehmens, wodurch die geplante Transaktion prozentual unerheblich ist.

Die Aktien wurden durch die Vesting-Phasen mehrerer Tranchen von Restricted Stock Units (RSUs) und Performance Share Units (RPSUs) erworben, die zwischen April 2021 und April 2023 gewährt wurden. Die Tranchengrößen reichen von 191 bis 1.565 Aktien und spiegeln übliche Praktiken bei Aktienvergütungen wider. Der Meldende gab an, im vorangegangenen Dreimonatszeitraum keine Verkäufe getätigt zu haben und bestätigte das Fehlen nicht offengelegter wesentlicher negativer Informationen.

Formular 144 ist eine Mitteilung über geplante, nicht abgeschlossene Verkäufe. Die Einreichung offenbart nicht die Identität des Verkäufers, ob ein Rule 10b5-1 Handelsplan besteht, noch die endgültigen Ausführungspreise. Angesichts der überschaubaren Transaktionsgröße und ihres Ursprungs aus routinemäßiger Anreizvergütung ist es unwahrscheinlich, dass dieses Ereignis den Aktienkurs von WLYB wesentlich beeinflusst, stellt jedoch einen Datenpunkt für Investoren dar, die Insider-Verkaufsmuster beobachten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SPERLING SCOTT M

(Last) (First) (Middle)
C/O THOMAS H. LEE PARTNERS, L.P.
100 FEDERAL STREET, 35TH FLOOR

(Street)
BOSTON MA 02110

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units (1) 06/28/2025 A 102.35 (2) (2) Common Stock 102.35 (2) 17,337.12 D
Explanation of Responses:
1. Convertible into Common Stock on a 1-for-1 basis.
2. Represents stock units credited to the Reporting Person's account as of June 28, 2025, at a price of $408.28 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control.
/s/ Melodie T. Morin, Attorney-in-Fact for Scott M. Sperling 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is the size of the proposed insider sale for WLYB disclosed in Form 144?

The notice covers 5,665 shares with an estimated market value of $250,053.

What percentage of John Wiley & Sons� outstanding shares does 5,665 shares represent?

The proposed sale equals roughly 0.013 % of the 44.62 million shares outstanding.

When is the earliest sale date mentioned in the Form 144 filing?

The filer lists an approximate sale date of July 1, 2025.

How were the shares to be sold originally acquired?

All shares originated from RSU and RPSU vesting events granted between April 2021 and April 2023.

Does the Form 144 confirm that the sale will occur?

No. Form 144 only provides notice of intent; actual sales will be confirmed, if completed, in subsequent Form 4 filings.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

152.65B
376.66M
0.2%
92.56%
1.1%
Diagnostics & Research
Measuring & Controlling Devices, Nec
United States
WALTHAM